DHE (Highly Pure)

Product Description

DHE (Highly Pure)
Catalog number: B2016155
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 5 mg
Molecular Weight or Concentration: 315.41 g/mol
Supplied as: Powder
Applications: a molecular tool for various biochemical applications
Storage: −20°C
Keywords: Dihydroethidium, Hydroethidine, 7-Diamino-10-ethyl-9-phenyl-9,10-dihydrophenanthridine
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ. Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations J Pain Res. 2020 Apr 30;13:859-864.
2: Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role Headache. 2006 Nov;46 Suppl 4:S212-20.
3: Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) – Then and Now: A Narrative Review Headache. 2020 Jan;60(1):40-57.
4: Yazdani M. Concerns in the application of fluorescent probes DCDHF-DA, DHR 123 and DHE to measure reactive oxygen species in vitro Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):578-82.
5: Khalife J, Lauritsen CG, Liang J, Shah SO. DHE-Induced Peripheral Arterial Vasospasm in Primary Raynaud Phenomenon: Case Report Neurohospitalist. 2019 Apr;9(2):113-115.
6: Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons Headache. 2010 Oct;50(9):1424-39.
7: Lipton RB, Albrecht D, Bermudez M, Hu J, Hussey E, Levy J. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults Headache. 2024 Mar;64(3):266-275.
8: Bérard A, Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes Headache. 2012 Jul-Aug;52(7):1085-93.
9: Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results Laryngoscope. 1998 Jul;108(7):962-7.
10: Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD(®) ) Device, in Healthy Adult Subjects Headache. 2019 Mar;59(3):394-409.

Products Related to DHE (Highly Pure) can be found at Chemicals